Keywords: Schizophrenia, US psychiatrits, Roche, Chugai, Bitopertin, Market forecasts, Decison Resources

Surveyed US psychiatrists would prescribe Roche/Chugai's bitopertin to 28% of their patients with negative symptoms of schizophrenia

Article | 30 May 2012

Print This

US psychiatrists surveyed by advisory firm Decision Resources indicate that they would prescribe Roche/Chugai’s bitopertin to 28% of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in